brain Logo
Annual report 2023/2024
DE
DE
  • Home
  • To our Shareholders
    • To our Shareholders
    • Letter from the CEO
    • Report from the Supervisory Board
    • Composition of the Supervisory Board
    • Corporate Governance Declaration
      • Corporate Governance Declaration
      • Statement of Conformity by the Management and Supervisory boards of BRAIN Biotech AG with the recommendations of the German Corporate Governance Code (DCGK) pursuant to Section 161 (1) Sentence 1 of the German Stock Corporation Act (AktG)
      • Relevant information about corporate governance practices
  • Company
    • Company
    • BRAIN Biotech at a Glance
    • Important Events in the fiscal year 2023/24
    • Why invest in BRAIN Biotech?
    • The BRAIN Biotech Share and the Capital Market
      • The BRAIN Biotech Share and the Capital Market
      • Capital market environment
      • The BRAIN Biotech Share
  • Group management report
    • Group management report
    • Basis of the Group
    • Economic and business report
      • Economic and business report
      • Macroeconomic and sector-related conditions
      • Business progress
      • Results of operations
      • Net assets and financial position
      • Employees
      • Overall statement on business progress
    • Events after the reporting date
    • Outlook
    • Report on risks and opportunities
      • Report on risks and opportunities
      • 1 Risk management at BRAIN Biotech AG
      • 2 Risks and opportunities at BRAIN Biotech AG
      • 3 Assessment of opportunities and risks in overall presentation
      • 4 Report on opportunities
      • Business-related opportunities
    • Takeover-relevant information pursuant to Section 315a of the German Commercial Code (HGB)
    • Corporate governance statement of conformity pursuant to Section 289f and Section 315d of the German Commercial Code (HGB)
  • Consolidated Financial Statements
    • Consolidated Financial Statements
    • Consolidated Balance Sheet
    • Consolidated Statement of Comprehensive Income
    • Consolidated Statement of Changes in Equity
    • Consolidated Statement of Cash Flows
    • Notes to the consolidated financial statements
      • Notes to the consolidated financial statements
      • I. General information
      • II. Basis of the consolidated financial statements
      • III. Accounting policies
      • IV. Segment reporting
      • V. Notes to the consolidated statement of comprehensive income
      • VI. Notes to the consolidated balance sheet
      • VII. Financial instruments / risks from financial instruments
      • VIII. Other information
    • Responsibility statement
    • Independent Auditor´s Report
  • Services
    • Services
    • Financial Calender
    • Contact
    • Social Media
Download Center
  • Home
  • Company

Company

  • BRAIN Biotech at a Glance
  • Important Events in the Fiscal Year 2023/24
  • Why invest in BRAIN Biotech?
  • The BRAIN Biotech Share and the Capital Market
BRAIN Biotech AG

Darmstädter Straße 34 – 36
64673 Zwingenberg
Germany

public@brain-biotech.com
Phone: +49 62 51 9331-0
Fax: +49 62 51 9331-11
www.brain-biotech-group.com
Copyright © 2025 BRAIN Biotech AG
Social Networks
Privacy policy Impressum - Legal notice